$87.83
7.63% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US03940C1009
Symbol
ACLX
Sector
Industry

Arcellx Stock price

$87.83
-2.08 2.31% 1M
+36.11 69.82% 6M
+32.33 58.25% YTD
+37.84 75.70% 1Y
+72.83 485.53% 3Y
+72.83 485.53% 5Y
+72.83 485.53% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-7.25 7.63%
ISIN
US03940C1009
Symbol
ACLX
Sector
Industry

Key metrics

Market capitalization $4.75b
Enterprise Value $4.24b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1,184.43
EV/Sales (TTM) EV/Sales 27.21
P/S ratio (TTM) P/S ratio 30.48
P/B ratio (TTM) P/B ratio 9.82
Revenue growth (TTM) Revenue growth 230.33%
Revenue (TTM) Revenue $155.82m
EBIT (operating result TTM) EBIT $-69.42m
Free Cash Flow (TTM) Free Cash Flow $3.58m
Cash position $574.46m
EPS (TTM) EPS $-0.75
P/E forward negative
P/S forward 42.18
EV/Sales forward 38.00
Short interest 8.33%
Show more

Is Arcellx a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Arcellx Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Arcellx forecast:

19x Buy
100%

Analyst Opinions

19 Analysts have issued a Arcellx forecast:

Buy
100%

Financial data from Arcellx

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
156 156
230% 230%
100%
- Direct Costs 4.12 4.12
58% 58%
3%
152 152
240% 240%
97%
- Selling and Administrative Expenses 76 76
36% 36%
49%
- Research and Development Expense 141 141
8% 8%
91%
-65 -65
54% 54%
-42%
- Depreciation and Amortization 4.12 4.12
58% 58%
3%
EBIT (Operating Income) EBIT -69 -69
52% 52%
-45%
Net Profit -40 -40
69% 69%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Arcellx directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arcellx Stock News

Neutral
Business Wire
11 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that it will present clinical data in a poster presentation from its Phase 1 study (abstract #4825) of anitocabtagene autoleucel (anito-cel) in patients w...
Positive
Seeking Alpha
2 months ago
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milesto...
Neutral
InvestorPlace
4 months ago
The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
More Arcellx News

Company Profile

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Rami Elghandour
Employees 130
Founded 2014
Website www.arcellx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today